Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 580 across all filing types
Latest filing 2026-06-08 Transaction in Own Shar…
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 96% confidence The document is a Next Day Disclosure Return (FF305) under Hong Kong Listing rules detailing changes in issued shares and treasury shares, specifically multiple share repurchases and cancellations by the issuer. It constitutes a report of the company buying back its own shares. This matches the Transaction in Own Shares category.
2026-06-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2026
Regulatory Filings Classification · 90% confidence The document is a periodic listing rule return (Form FF301) filed to the Hong Kong Stock Exchange detailing monthly movements in issued shares, treasury shares, public float confirmations, and related share schemes. It is a standard regulatory compliance filing rather than a financial report, earnings release, board change announcement, or proxy material. It does not contain narrative management discussion or investor presentation slides, nor is it announcing publication of another report—itself constitutes a regulatory submission. Therefore, it falls under the general Regulatory Filings category (RNS).
2026-06-03 English
VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE PROMOTION SERVICE AGREEMENT WITH PRIMEGENX THERAPEUTICS IN RELATION TO PUMECITINIB GEL
Regulatory Filings Classification · 90% confidence The document is a voluntary announcement by Simcere Pharmaceutical Group concerning the entry into an exclusive promotion service agreement. It does not contain financial results, earnings, management changes, share issuances, dividends, or proxy materials. It is an operational/corporate announcement of a business collaboration, which does not fit any specific category and thus defaults to Regulatory Filings (RNS).
2026-06-01 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 98% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Listing Rules, detailing changes in issued and treasury shares, including detailed on-market share repurchases and cancellation data. It is a report of the company buying back its own shares. This matches the “Transaction in Own Shares” category, code POS.
2026-05-22 English
NOTIFICATION LETTER AND REPLY FORM TO NON-REGISTERED HOLDERS: NOTICE OF PUBLICATION OF CIRCULAR AND NOTICE OF ANNUAL GENERAL MEETING
Report Publication Announcement Classification · 97% confidence The document is a notification letter and reply form informing non-registered holders that the Company’s circular and notice of the Annual General Meeting (“Current Corporate Communication”) have been published online. It does not contain the actual AGM materials or financial data, but merely announces the publication of those documents and provides instructions on how to obtain printed copies. Under the “menu vs meal” rule, this is an announcement of a report’s publication, not the report itself. Therefore, it should be classified as a Report Publication Announcement (RPA).
2026-05-21 English
NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS: NOTICE OF PUBLICATION OF CIRCULAR, NOTICE OF ANNUAL GENERAL MEETING AND PROXY FORM
Report Publication Announcement Classification · 92% confidence The document is a shareholder notification letter advising registered shareholders of the publication of the company’s circular, notice of Annual General Meeting and proxy form on its website and HKEXnews, and provides instructions for accessing or requesting printed copies. It does not contain the actual AGM materials or substantive financial content, but merely announces the availability of those materials. Under the “menu vs meal” rule, this is a report publication announcement rather than the report itself.
2026-05-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.